This commentary addresses the possible reasons for treatment gaps between recommended therapy for patients with CKD, and the realities of current practices, and examines new developments that may bridge the gap.
Susan E. Funk, MBA
Advertisement
Articles by Susan E. Funk, MBA
A budget-impact model illustrates the economic outcomes associated with renoprotective therapy on privately insured patients with advanced kidney disease.
Advertisement
Latest Updated Articles
- Implementing Guideline-Recommended Therapy for Patients With CKD: Is Hope on the Horizon?
Published: April 23rd 2015 | Updated:
- The Economics of Renoprotective Therapy in Advanced Diabetic Kidney Disease
Published: February 6th 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
2
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
3
Biosimilar Stivant Shows Noninferior Efficacy and Comparable Safety to Reference Bevacizumab
4
FDA Expands Adalimumab-Aaty For Pediatrics, Adolescents With Rare Inflammatory Conditions
5
